Pfizer (PFE) Faces a High Hurdle This Friday to Appear Competitive with Sarepta (SRPT) - Cantor
June 25, 2019 7:14 AM
Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating and $231.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after hosting ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
